Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
73% of patients with prior exposure to covalent BTK inhibitors responded
Source: medpagetoday.com
Barbara Eichhorst News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Barbara Eichhorst. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Barbara Eichhorst Today - Breaking & Trending Today
Venetoclax Plus Obinutuzumab With or Without Ibrutinib Improves Undetectable MRD Rates in Fit Patients With CLL
The combination of venetoclax and obinutuzumab with or without ibrutinib generated higher rates of undetectable minimal residual disease (MRD) and progression-free survival vs chemoimmunotherapy in fit patients with chronic lymphocytic leukemia.
Source: onclive.com
CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy
A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.
Source: medscape.com
Time-limited venetoclax-based regimens prolong PFS vs. chemoimmunotherapy in CLL
Time-limited venetoclax, obinutuzumab and ibrutinib or venetoclax plus obinutuzumab prolonged PFS compared with chemoimmunotherapy among fit, previously untreated patients with chronic lymphocytic leukemia, according to study results.The preplanned interim analysis of the international, randomized phase 3 GAIA/CLL13 trial, presented during European Hematology Association Hybrid 2022 Congress,
Source: healio.com
Venetoclax Combos Improve Progression-Free Survival in CLL
Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern.
Source: medscape.com